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Abstract
Background and Methods: Little is known about antiretroviral therapy (ART) outcomes in prisoners in Africa. We conducted
a retrospective review of outcomes of a large cohort of prisoners referred to a public sector, urban HIV clinic. The review
included baseline characteristics, sequential CD4 cell counts and viral load results, complications and co-morbidities,
mortality and loss to follow-up up to 96 weeks on ART.
Findings: 148 inmates (133 male) initiated on ART were included in the study. By week 96 on ART, 73% of all inmates
enrolled in the study and 92% of those still accessing care had an undetectable viral load (,400copies/ml). The median CD4
cell count increased from 122 cells/mm
3 at baseline to 356 cells/mm
3 by 96 weeks. By study end, 96 (65%) inmates had ever
received tuberculosis (TB) therapy with 63 (43%) receiving therapy during the study: 28% had a history of TB prior to ART
initiation, 33% were on TB therapy at ART initiation and 22% developed TB whilst on ART. Nine (6%) inmates died, 7 in the
second year on ART. Loss to follow-up (LTF) was common: 14 (9%) patients were LTF whilst still incarcerated, 11 (7%) were
LTF post-release and 9 (6%) whose movements could not be traced. 16 (11%) inmates had inter-correctional facility transfers
and 34 (23%) were released of whom only 23 (68%) returned to the ART clinic for ongoing follow-up.
Conclusions: Inmates responded well to ART, despite a high frequency of TB/HIV co-infection. Attention should be directed
towards ensuring eligible prisoners access ART programs promptly and that inter-facility transfers and release procedures
facilitate continuity of care. Institutional TB control measures should remain a priority.
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Introduction
South Africa has a high incarceration rate of 413/100 000
population [1]. Risk factors for incarceration echo those of HIV
acquisition: being young, Black and male, poverty, dysfunctional
family and/or social relationships, lower educational attainment,
unemployment and drug/alcohol use (although intravenous drug
use is uncommon) [2–4]. Over one third of inmates are below 25
years of age [5]. An exceptionally high violent crime rate results in
almost 30% of inmates being incarcerated in maximum security
facilities, with 47% of prison sentences being ten or more years in
duration [5]. On average, South Africa’s 240 correctional facilities
operate at 137% of intended capacity [5].
HIV is an important health problem in prisons globally [2,3].
South Africa, with approximately 5.6 million HIV-infected
individuals, has the world’s largest single national burden of
HIV [6]. HIV prevalence in prisons often outstrips that in the
general population [2]. In South Africa over 16% of adults are
HIV-infected [6], increasing to 24% for Black males aged 25–49
years [7]. HIV prevalence in South African prisons is estimated to
be between 20–40% [2,4,8]. During a recent national HIV
counseling and testing campaign, 53 000 inmates were tested;
19% of whom tested HIV-positive [9].
HIV increases susceptibility to tuberculosis (TB). South Africa
records the third highest TB incidence globally [10], notifying 948
cases/100 000 population [11]. 70% of these TB patients are
HIV-infected [11]. Internationally, TB prevalence amongst
prisoners is significantly higher than in the general population
[8,12–16]. Thus, in South Africa, HIV-infected inmates are at
particularly high risk for developing active TB. Escalating rates of
TB and HIV may explain the 800% increase in mortality recorded
in South African prisons between 1995 and 2005 [17].
Antiretroviral therapy (ART) significantly reduces HIV/AIDS-
associated morbidity and mortality [18]. In state prisons in the
United States, between 1995 and 1999, AIDS-related mortality fell
over 75% - seemingly following increased ART availability [19].
In New York City, AIDS-related mortality declined from 41 to 6
deaths/10 000 inmates between 1990 and 1998; rates for other
causes of mortality remaining unchanged [20]. Importantly, ART
significantly reduces TB incidence [21,22] and TB-associated
mortality [23].
In Connecticut, 59% of prisoners on ART for over 6 months
were virologically suppressed (viral load ,400 copies/ml) with a
mean CD4 cell count increase of 74 cells/mm
3 [24]. Few studies
report HIV-related health outcomes among prisoners on ART in
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33309resource-limited countries. In Malawi, after 12 months on ART,
61% of inmates were alive and accessing treatment [25]. In
Thailand, 72% of 88 inmates were accessing care after a median
18 months on ART [26].
South Africa boasts the world’s largest ART programme with
ever-expanding coverage facilitating treatment access for special
populations, including inmates [7]. The Department of Correc-
tional Services introduced an HIV Treatment Policy in 2007 [27].
ART access for prisoners has gradually improved since [27]. 8 091
inmates (5% of all inmates) are currently on ART [9]. 9% of
facilities now provide on-site ART services but inmates in other
facilities continue to encounter barriers to off-site ART access
[28]. Considering 360 000 inmates are released back into the
community in South Africa each year [8], successful provision of
ART for prisoner populations – both during incarceration and
following release - is of great public health importance. This
descriptive study reports on HIV-related health outcomes of




The study was conducted at the outpatient adult ART clinic at
Chris Hani Baragwanath Hospital, a 2 700 bed public-sector
university hospital in Soweto, South Africa. The clinic manages
over 4 000 patients on ART. Free ART has been provided since
the public-sector ART programme began in April 2004. The
typical starting regimen at the time of the study was stavudine,
lamivudine and efavirenz. Patients are seen weekly or fortnightly
during ART preparation and then 2, 4, 8 and 12 weeks after
initiation. Once responding well to treatment, review occurs 3 or 4
monthly. Patients with complex co-morbidities, advanced disease
or complications are seen more frequently.
Prison site
Inmates included in this study were incarcerated in a prison
which was situated in the hospital catchment area. Prisoners
mostly came from nearby communities, fewer were from distant
areas. The prison, like most, is overcrowded and understaffed; cells
built for 40 prisoners holding up to 100 [29]. The prison houses
between 10 000 and 11 000 inmates. The maximum security
section, which accounts for approximately 3 300 inmates, receives
an average of 25 new admissions per day (Monday to Friday) and
moves or transfers out approximately 40 inmates per week
(personal communication). Most inmates in this study were from
maximum security and many were serving long sentences.
Study population
All adult (.18 years) inmates enrolled onto ART at the clinic
between April 2004 and February 2008 were included in the
study. HIV testing was voluntary and often occurred only once
inmates became clinically ill. Only ART eligible inmates were
referred off-site. ART eligibility, defined by national guidelines,
was limited to CD4 count ,200 cells/mm
3 and/or World Health
Organization (WHO) stage 4 disease. Inmates with higher CD4
cell counts were excluded as they were not referred to the clinic.
The cohort included ART-naı ¨ve inmates and ART-experienced
inmates transferred in from other ART sites (9 inmates) during the
study period. Prison medical staff did not provide any ART-
related care and clinic doctors provided no outreach services at the
prison. Inmates had access to prison medical staff that either
managed problems on-site or referred them to hospital as needed.
Inmates’ medication was collected from the clinic by the guards
who accompanied inmates off-site. Once collected, inmates self-
retained their ART drugs, storing them in their cell.
Procedures
Inmates were identified using the clinic’s booking records. A
retrospective cohort analysis was performed. Data was collected
from ART clinic and laboratory records until inmates had been on
ART for 96 weeks (or closest available results) or were no longer in
care at the clinic. Prison medical records were unavailable.
Baseline information comprised age, sex, past history of
opportunistic infections, WHO stage, details of previous ART
exposure, baseline CD4 count and viral load, hepatitis B and C
status and syphilis serology, ART initiation date and regimen
choice. Indicators for progress on ART included sequential CD4
and viral load results at 24, 48 and 96 weeks (or closest available
result), hospitalizations, new opportunistic infections, TB events on
ART, drug toxicity, and any drug changes. Viral load ,400
copies/ml defined virological suppression. Outcome was assessed
by death, loss to follow-up and retention in care following release.
Educational attainment, reason for incarceration, sentence
duration, risk factors for incarceration and HIV and history of
substance use or mental illness were not routinely recorded and
hence are not reported.
Inter-facility transfers and releases meant some records were
incomplete. When data were unavailable, the inmate was excluded
from the relevant data set(s), resulting in a variable denominator.
Clinical files for five inmates were not located; laboratory records
provided minimum data comprising demographic information
and laboratory results.
Ethics Statement
The study was approved by the Human Research Ethics
Committee, University of Witwatersrand, Johannesburg and by
the Department of Correctional Services Research Committee,
Pretoria. Two files were excluded because inmates declined
consent for their records to be included.
Results
Baseline Characteristics
133 (90%) inmates were male, with a median age of 32 years
(range 21–54 years).
The median baseline CD4 cell count was 122 cells/mm
3 (range
4–241). 29 (21%) inmates had CD4 cell count ,50 cells/mm
3.
At baseline, 71 of 148 (51%) inmates had WHO stage 3
conditions: 69 had pulmonary TB, 2 had chronic diarrhea. WHO
stage 4 conditions at baseline comprised 14 patients with extra-
pulmonary TB, 3 with Kaposi’s sarcoma and one with non-
Hodgkin’s lymphoma. One patient had Hodgkin’s lymphoma. 66
(46%) inmates displayed prior hepatitis B exposure of whom 13
(9%) were surface antigen positive – suggesting active disease. One
patient was hepatitis C PCR-positive. All inmates tested RPR-
negative for syphilis.
Virological & Immunological Outcomes (Table 1)
108 (92%) of 118 inmates retained on treatment through 96
weeks (or closest available result) were virologically suppressed
(viral load ,400 copies/ml), equating to 73% of the 148 inmates
initially included in the study. Seven patients switched to second-
line drugs due to virological failure (national guideline definition:
viral load .5 000 copies/ml on at least 2 occasions). Inmates’
CD4 cell counts steadily increased from 122 cells/mm
3 at baseline
to 356 cells/mm
3 at 96 weeks on ART. After 2 years on treatment,
Prison Inmates on ART




Hospitalization. 37 (26%) patients had a total of 45
admissions, of which 13 (29%) occurred within the first 6 months
on ART. TB was the most common reason for admission (17/45,
38%). One patient, who was admitted twice, had both TB and
mycobacterium avium complex. Other reasons for hospitalization
included: other infections (lower respiratory tract infection (LRTI)
(5 admissions), chronic active hepatitis B, gastroenteritis, meningitis,
meningitis plus LRTI); surgery (human papilloma virus wart
resection (2), bilateral breast reduction for gynecomastia,
decortication for TB empyema, fistulotomy, incision and drainage
of inguinal abscess, esophageal dilatation for achalasia, small bowel
obstruction following prior abdominal TB) and other medical
conditions (deep vein thrombosis (3), symptomatic hyperlactatemia
(2), acute psychosis, diabetes mellitus, drug overdose, non-
Hodgkin’s lymphoma, obstructive jaundice).
Complications. Drug toxicity was common.Overall 75 (53%)
inmates experienced 100 different side-effects of variable severity
including: painful peripheral neuropathy (32 patients), symptomatic
hyperlactatemia (22), lipodystrophy (21), gynecomastia (13) and
hyperlipidemia (12). The ART regimen was changed in 38 (23%) of
143 inmates. The most common reason for drug switch was
stavudine-associated drug toxicity as this was being prescribed at
40 mg twice daily for inmates weighing over 60 kg (as per national
guidelines at the time). Twelve (8%) of 143 inmates were diagnosed
with depression, although none severe enough to warrant
admission.
Tuberculosis (Table 2). Out of 133 inmates for whom it was
recorded, 44 (33%) were on TB treatment at ART initiation. 86
(61%) of 141 patients gave a history of prior and/or current TB. TB
was common before ART initiation; at ART initiation and once
established on ART. New TB events once on ART occurred as
follows: four in the first 12 weeks, four in weeks 13–24, seven in
weeks 25–48, seven in weeks 49–72 and nine in weeks 73–96. In
four cases timing was unclear. Pulmonary and extra-pulmonary
disease (15 and 16 cases respectively) was equally represented
amongst new episodes. Four remaining cases were treated
empirically or the site was not recorded. By study end, 96 (65%)
inmates had ever received one or more courses of TB treatment. Of
eight inmates initiating ART within one month after starting TB
treatment, five developed immune reconstitution inflammatory
syndrome (IRIS). In total, six (10%) inmates treated during the
study had confirmed multidrug resistant TB of whom four had a
prior history of TB.
Mortality. By study end, nine (6%) patients had died - two
deaths occurred in the first four months; all others occurred a year
or more after ART initiation. The cause of death (severe sepsis)
was known for one patient who died in hospital. The cause was not
recorded for eight deaths occurring in prison.
Loss to Follow-up. 34 (23%) inmates were lost to follow-up:
14 (9%) while still incarcerated; 11 post-release and nine (6%)
whose movements could not be traced. Inmates lost to follow-up
had a lower median baseline CD4 count of 106 cells/mm
3 (range
7–217). During the study period, 50 (34%) inmates were moved:
16 (11%) had inter-correctional facility transfers and 34 (23%)
were released, of whom 23 (68%) returned to the HIV clinic, with
four arranging transfers to other ART sites. It is unknown whether
the 11 (32%) patients lost to follow-up post-release accessed ART
elsewhere.
Discussion
Inmates in this study demonstrated very good clinical,
immunological and virological outcomes following ART initiation,
despite high levels of treated TB. 92% of inmates remaining on
treatment through 96 weeks were virologically suppressed.
Considering the low average baseline CD4 cell count, mortality
and non-TB associated morbidity rates were relatively low. TB
was the most common co-morbidity: 65% of inmates had
experienced one or more episodes of TB by study end. Inter-
facility transfers and inmate release into the community were
common reasons for loss to follow-up.
Virological suppression in this prison population was equivalent
to that reported in South African, community-based, public-sector
ART studies: one study reported 90.8% virological suppression at
six months on ART [30], another reported 69.7% virological
suppression after 24 months on ART [31]. Inmate populations in
Table 1. Virological and immunological outcomes at 24, 48 and 96 weeks.
Week Median CD4 cell count/mm
3 (IQR) % Inmates still on ART* with viral load ,400 copies/ml % Total cohort
{ with viral load ,400 copies/ml
Baseline 122 (50–156)
24 196 (134–269) 91 75
48 246 (179–330) 91 78
96 356 (254–441) 92 73
*Number of inmates virologically suppressed (111, 115, 108)/number of available viral load results at 24, 48 and 96 weeks or closest available result (122, 126, 118
respectively).
{Number of inmates virologically suppressed at 24, 48 and 96 weeks/all 148 inmates including those who died, defaulted, failed treatment or were transferred out/lost
to follow-up.
Abbreviation: IQR: inter-quartile range.
doi:10.1371/journal.pone.0033309.t001
Table 2. TB rates pre-ART, at ART initiation and on ART.
TB Event % N/Denominator
Total giving history of TB disease at baseline 61 86/141
Previous TB therapy 28 42/141
On TB therapy at ART initiation 33 44/133
Total inmates with new TB episode on ART* 21 31/148
Number of confirmed MDR TB cases 10 6/63
*4 of 31 inmates had 2 episodes of TB once on ART=35 new episodes of TB.
Abbreviations: TB: Tuberculosis; ART: antiretroviral therapy; MDR: multidrug
resistant.
doi:10.1371/journal.pone.0033309.t002
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59% virological suppression at six months on ART [24,32].
However, in developed nations, intravenous drug use amongst
HIV-infected inmates frequently impacts treatment adherence and
rates of significant co-morbidities [2,33]. In South Africa, although
alcohol and substance misuse is prevalent, intravenous drug use
remains uncommon, perhaps partially explaining the noticeably
better virological outcomes in this cohort [2,8]. Directly Observed
Therapy (DOTS) for ART has previously been evaluated, with
conflicting results [34–36]. The success of a non-DOTS or patient-
retained approach [33] in this cohort suggests DOTS would yield
limited, if any, benefit and may even, as seen elsewhere [37],
impact acceptability and uptake of ART services.
The high rate of virological suppression attained in this cohort
has significant public health implications. Recently, the HPTN
052 study convincingly showed that sustained virological suppres-
sion, following ART initiation, resulted in a 96% reduction in
sexual HIV transmission in sero-discordant heterosexual couples
[38]. Considering high levels of sexual violence, tattooing practices
and violent disputes within prisons, attaining virological suppres-
sion in inmates on ART potentially represents an important means
of reducing HIV transmission within prisons.
At baseline, inmates had advanced HIV with low median CD4
cell counts, as commonly seen in both prison and community
settings. In Thailand, 81% of inmates initiating ART had WHO
stage 3 or 4 disease [26]. One large community-based South
African study reported a median baseline CD4 count of 103 cells/
mm
3 at ART initiation, with 27% having CD4 counts below 50
cells/mm
3 [39]. Another South African study reported a median
baseline CD4 count of 125 cells/mm
3 at ART initiation [40].
Initiating ART in those with advanced HIV is associated with
higher rates of ART-associated complications, TB and death
[41,42]. Considering mortality may be up to 50% higher in those
initiating ART with advanced disease [41], the low early mortality
in this group is striking [30,31]. The relatively high hospitalization
rate may have been due to prevalent advanced disease combined
with ready hospital access via the ART clinic. The median CD4
cell counts on ART compared favorably with other South African
cohorts (288 cells/mm
3 at two years on ART) [31] and other
inmate cohorts (74 cells/mm
3 at six months) [24]. The frequency
of drug toxicities likely arose due to use of twice daily stavudine at
40 mg. Tenofovir is now available in the public-sector so NRTI-
associated toxicities occur less commonly. However, considering
almost half of inmates had been exposed to hepatitis B, hepatitis B
screening will prove an important step before discontinuing
tenofovir in those requiring switch to second-line agents due to
virological failure [43].
One third of inmates experienced inter-facility transfers or
release into the community. Loss to follow-up commonly occurred
at these times. Considering inmates’ encouraging ART outcomes
whilst in prison, any breakdown in continuity of care during
inmate movements represents a considerable risk to the sustain-
ability of such positive outcomes [24,44]. Currently no standard-
ized approach exists to ensure inmates initiating ART in prison
successfully connect with community-based, public-sector ART
sites post-release. Inmates presenting to community-based clinics
without a standard transfer letter may encounter difficulties
accessing routine follow-up and consistent ART provision post-
release [45]. Disrupted care during inter-facility transfers and post-
release has been identified as problematic in other prison-based
studies [24,32,46,47]. Such treatment disruptions, and subsequent
loss of virological suppression, negatively impact individual
patients and public health [33]. Policies should be developed
and implemented to address this. Protocols facilitating continuity
of care during inmate movement minimize treatment interrup-
tions, ensuring better virological outcomes [46,47]. Such ‘linkage
to care’ or case management interventions have proven highly
effective elsewhere [48–50]. One study reported that 90% of HIV-
infected inmates continued accessing community-based HIV care
post-release following the implementation of discharge planning
and case management [16]. A recent literature review identified
four additional elements of transitional care that significantly
impact on treatment outcomes for HIV-infected prisoners post-
release: continuity of ART provision; concurrent management of
substance use disorders; continuity of management for any mental
health conditions and interventions to enhance secondary
prevention via reduction in HIV-associated risk-taking behaviors
[49].
TB disease was common before ART initiation, at initiation and
once established on ART. In comparison, a South African
community-based cohort reported TB rates of 14% prior to
ART initiation, 5% at initiation and 8% after initiation [42].
Worldwide, TB in prisons exceeds that in the general population
[12–15]. The increased vulnerability to TB seen in HIV-infected
individuals may explain why this cohort of HIV-infected inmates
demonstrated markedly higher TB rates than reported in studies of
general inmate populations [8,12–16]. The high proportion of
inmates on TB treatment at ART initiation may have been
because TB diagnosis triggered their referral to the clinic or
because pre-ART screening identified inmates with undiagnosed
TB. The retrospective nature of the study precludes definite
conclusions about whether TB developing once on ART was
already present but undiagnosed at ART initiation. However, TB
rates throughout the study remained constant and were not higher
in the first 3–6 months, suggesting that TB diagnosis pre-ART was
not frequently missed. Further research, involving a larger inmate
cohort initiating ART, might clarify these points and validate the
findings regarding TB frequency. As reported elsewhere, ART-
associated TB IRIS was most common when ART was initiated
within one month of TB treatment commencing [51]. The MDR
rate in this cohort was slightly higher than rates seen in the
community but the low numbers mean this finding would need
corroboration [52]. The frequency of TB in this study indicates a
need for comprehensive implementation of the WHO’s ‘3 I’s’
approach to TB control (intensified case finding, isoniazid
prophylactic therapy and infection control) within correctional
facilities [53] and timely ART initiation in TB/HIV co-infected
inmates with CD4 cell counts ,350 cells/mm
3 (as per updated
South African National guidelines) [43].
The study has limitations usually associated with retrospective
reviews. Additionally, the study took place soon after Department
of Correctional Services committed to providing HIV care for
inmates and so HIV testing uptake was low and off-site referral
encountered many barriers. This explains the small cohort size
despite the combination of high HIV prevalence and a large
prison population. Referral bias may mean this cohort is not fully
representative of all ART-eligible inmates. Inmates who accessed
HIV testing and secured off-site referral may represent a
particularly motivated group of individuals, possibly resulting in
excellent treatment adherence. The low mortality seen in this
group may also be due to very ill inmates being deemed too sick
for off-site care. Consequently, results may not be reproducible if
ART care is provided on-site, within a prison facility, or at a less
sophisticated hospital.
In conclusion, prisoners do well on ART if referred for
treatment in a timely manner. Despite the small cohort size, this
study sets an important benchmark for prison ART programmes
in resource-limited settings. Considering the individual and public
Prison Inmates on ART
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ART initiation, TB control, and linkage to care during transfers
and post-release should be prioritized by prison programmes.
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